The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis
C.E.M. Griffiths; D. Thaçi; S. Gerdes; P. Arenberger; G. Pulka; K. Kingo; J. Weglowska; N. Hattebuhr; J. Poetzl; H. Woehling; G. Wuerth; M. Afonso
Author Information: Dermatology Centre
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.